Dr. Christopher Barbieri - Genomic Testing For Prostate Cancer Patients
To request an appointment with Dr. Barbieri in NYC, please call (212) 746-5562.
Dr. Barbieri discusses Genomic Testing For Prostate Cancer Patients, and how this may impact risk stratification and decision to pursue treatment(s).
To learn more about Dr. Barbieri, please visit our website at: https://urology.weillcornell.org/christopher-e-barbieri
Dr. Christopher Barbieri - Genetic Testing For Prostate Cancer Risk Assessment
To request an appointment with Dr. Barbieri in NYC, please call (212) 746-5562.
Dr. Christopher Barbieri discusses recent advances in genetic testing that allow patients to have blood or saliva sampled to help evaluate their risk of developing prostate cancer.
To learn more about prostate cancer, please visit our website at: https://urology.weillcornell.org/prostate-cancer
Dr. Jim Hu - Does Prostatectomy Cure Prostate Cancer?
If you would like an appointment, please call us at (646) 962-9600.
Dr. Jim C. Hu discusses various factors that contribute to whether a radical prostatectomy has a curative outcome in any given patient.
To request an appointment with an NYC Urologist specializing in prostate cancer at Weill Cornell Medicine, please visit: https://urology.weillcornell.org/request-appointment
MRI-Ultrasound Fusion Guided Focal Cryotherapy of Prostate Cancer at Weill Cornell Urology
If you would like to make an appointment to see a urologist specializing in prostate cancer, please call our office at (646) 962-9600.
This educational video discusses the MRI-Ultrasound Fusion Guided Focal Cryotherapy of Prostate Cancer, which is an innovative procedure performed at Weill Cornell Medicine.
You can learn more about prostate cancer treatment and Weill Cornell Medicine's expertise by visiting our prostate cancer resources pages.
Research on SPOP Prostate Cancer Subtype Prognosis and PSA levels
Dr. Christopher Barbieri was interviewed as a co-senior author on new prostate cancer research from Weill Cornell Medicine & colleagues, regarding the interpretation of PSA levels in patients with the SPOP prostate cancer subtype.
"These findings are counterintuitive," said co-senior author Dr. Christopher Barbieri, an assistant professor of urology at Weill Cornell Medicine. "In general, if your PSA is higher, the cancer is more dangerous. However, this study found that tumors associated with a high PSA and SPOP mutations were less dangerous."
Treating prostate cancer with cryotherapy: Richard Hayden's success
Richard Hayden is a quick-witted 80-year-old living in Manhattan. He enjoys being healthy and active; taking advantage of all that New York City has to offer during his retired years.
Earlier this year, during a routine visit with his primary care physician, he was told that his prostate-specific antigen (referred to as "PSA") levels were abnormally high. Richard was then referred to Dr. Loo, a urologist at Weill Cornell Medicine. After several more blood tests, Dr. Loo became concerned about the potential of prostate cancer.
Cryotherapy and prostate cancer
If you've been diagnosed with prostate cancer, determining your treatment plan can be stressful and overwhelming. There is no single "best" course of action; it depends on you, your lifestyle goals, and your specific type of cancer.
Prostate cancer can be treated with active surveillance, radiation therapy, medical & hormone therapies, surgery, and various ablation procedures such as cryotherapy. Prostate cancer specialists, such as the Urologic Oncologists at Weill Cornell Medicine, will help you customize the right treatment plan for you.
Dr. Barbieri - Interview with an Expert: Active Surveillance
Christopher Barbieri, M.D., Ph.D., Assistant Professor in Urology and in Cell & Developmental Biology at Weill Cornell Medicine, was interviewed by the Prostate Cancer Foundation on active surveillance for prostate cancer patients. He addresses many of the common questions that patients and providers ask regarding eligibility for active surveillance and treatment protocol.
Weill Cornell Medicine Research Highlighted by Prostate Cancer Foundation’s “Top 5 Prostate Cancer Research Stories of 2017”
In January 2018, the Prostate Cancer Foundation recognized the developments of PSMA radionuclide therapy as one of the top 5 research stories of 2017, highlighting the recent work from Weill Cornell Medicine’s Department of Urology as a driving force behind this effort.
